Varithena® Foam Sclerosant

Varithena®: Comprehensive* treatment for GSV system incompetence1,2

Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Varithena® lets you easily treat any vein shape and a wide range of sizes, above and below the knee*.

  • GSV, AASV, PASV,† and visible varicosities
  • Small, medium, and large diameters (including ≥12 mm)
  • Tortuous, recurrent, above and below the knee
  • CEAP clinical class 2-6
  • 84% of patients had virtually no symptoms one year after treatment

No tumescent anesthesia

Cohesive, low-nitrogen microfoam for consistent performance

MECHANISM OF ACTION >

Novel efficacy endpoints in clinical trials

EFFICACY >

Safety evaluated in 1333 patients in 12 clinical trials

SAFETY PROFILE >

Support to help you integrate Varithena® into your practice

 
Varithena® treats a range of vein anatomies and diameters*
Mechanism of action

INDICATIONS

Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

IMPORTANT SAFETY INFORMATION

The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.

Follow Us